Advertisement
Screener

Alkermes plc. (ALKS) Stock Repurchase Program, Authorized Amount (Deprecated 2014-01-31)

2.8 / 5 stars · 68/120 Roast Me

Alkermes plc. Stock Repurchase Program, Authorized Amount (Deprecated 2014-01-31)

Alkermes plc. (ALKS) reported Stock Repurchase Program, Authorized Amount (Deprecated 2014-01-31) of $215.00 million for the 1-month period ending 2011-09-30, per its 10-K filed 2012-05-18.

Discontinued › Notes › Equity

us-gaap:StockRepurchaseProgramAuthorizedAmount · last filed 2014-02-27

  • 2011-09-30: Stock Repurchase Program, Authorized Amount (Deprecated 2014-01-31) 1 month $215.00M.
  • 2011-09-16: Stock Repurchase Program, Authorized Amount (Deprecated 2014-01-31) 0 month $215.00M.
Period endStock Repurchase Program, Authorized Amount (Deprecated 2014-01-31) 0 monthStock Repurchase Program, Authorized Amount (Deprecated 2014-01-31) 1 month
2011-09-30$215.00M
10-K · filed 2012-05-18
2011-09-16$215.00M
10-KT · filed 2014-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76